Trial Profile
Fingolimod for the prediction of disability progression in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2016 New trial record